Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Cardiovascular complications of systemic therapy in non-small-cell lung cancer
M Zaborowska-Szmit, M Krzakowski… - Journal of Clinical …, 2020 - mdpi.com
Cardiovascular diseases may determine therapy outcomes of non-small-cell lung cancer
(NSCLC). The evidence for how iatrogenic cardiovascular complications contribute to …
(NSCLC). The evidence for how iatrogenic cardiovascular complications contribute to …
The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity
X Zhang, Y Gao, B Yang, S Ma, W Zuo, J Wei - International …, 2023 - Elsevier
As the intensive anti-tumour therapy and combination of multiple anti-tumour drugs,
cardiotoxicity events caused by anti-tumour drugs have also increased significantly, and the …
cardiotoxicity events caused by anti-tumour drugs have also increased significantly, and the …
[HTML][HTML] Smoking, diabetes mellitus, and previous cardiovascular disease as predictors of anticancer treatment-induced cardiotoxicity in non–small-cell lung cancer: a …
H Kobat, I Elkonaissi, E Foreman, M Davidson… - Clinical Lung Cancer, 2024 - Elsevier
Purpose Cardiotoxicity is a common and under-reported side effect of tyrosine-kinase
inhibitors (TKI) and immune checkpoint inhibitors (ICI). Baseline risk factors may help in risk …
inhibitors (TKI) and immune checkpoint inhibitors (ICI). Baseline risk factors may help in risk …
[HTML][HTML] Exercise in cancer care for people with lung cancer: A narrative synthesis
Objective Lung cancer is the second most common cancer diagnosed worldwide, resulting
in significant physical and psychological consequences. In this narrative review, we explore …
in significant physical and psychological consequences. In this narrative review, we explore …
[HTML][HTML] Prediction models for treatment-induced cardiac toxicity in patients with non-small-cell lung cancer: A systematic review and meta-analysis
F Tohidinezhad, F Pennetta, J van Loon… - Clinical and …, 2022 - Elsevier
Background To maximize the likelihood of positive outcome in non-small-cell lung cancer
(NSCLC) survivors, potential benefits of treatment modalities have to be weighed against the …
(NSCLC) survivors, potential benefits of treatment modalities have to be weighed against the …
Ion channels in lung cancer: biological and clinical relevance
C Capitani, G Chioccioli Altadonna… - Frontiers in …, 2023 - frontiersin.org
Despite improvements in treatment, lung cancer is still a major health problem worldwide.
Among lung cancer subtypes, the most frequent is represented by adenocarcinoma …
Among lung cancer subtypes, the most frequent is represented by adenocarcinoma …
Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials
J Zhao, Z Ma, H Li, D Sun, Y Hu, C Zhang… - Expert Opinion on …, 2023 - Taylor & Francis
Background Anaplastic lymphoma kinases (ALK) tyrosine kinase inhibitors (TKIs) are
effective and safe targeted therapies used in advanced ALK-positive non-small cell lung …
effective and safe targeted therapies used in advanced ALK-positive non-small cell lung …
Cardiovascular complications associated with contemporary lung cancer treatments
K Sase, Y Fujisaka, M Shoji, M Mukai - Current Treatment Options in …, 2021 - Springer
Opinion statement Lung cancer is the most common form of cancer in humans and the
leading cause of cancer-related death worldwide. Traditionally, lung cancer has been …
leading cause of cancer-related death worldwide. Traditionally, lung cancer has been …
Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in …
Objectives In recent years immunotherapy has escalated to frontline treatment options for
metastatic non-small cell lung cancer. Cardiovascular toxicity from chemotherapeutic agents …
metastatic non-small cell lung cancer. Cardiovascular toxicity from chemotherapeutic agents …
Treatment‐related cardiovascular events in patients with non–small cell lung cancer: Evidence from real‐world data with a competing risks approach
TN Tran, S Lee, HJ Kim, Y Lee, TM Tu, JH Choi… - Cancer, 2024 - Wiley Online Library
Background Understanding cancer treatment–related cardiovascular (CV) events is
important for cancer care; however, comprehensive evaluation of CV events in patients with …
important for cancer care; however, comprehensive evaluation of CV events in patients with …